Carfilzomib Market Expanding with Growing Demand for Cancer Therapies | Dataintelo https://dataintelo.com/report/global-carfilzomib-market The global Carfilzomib Market is witnessing rapid growth, projected to reach USD 6.4 billion by 2032, growing at a CAGR of 9.8% from USD 2.5 billion in 2023. This growth is primarily driven by the rising prevalence of multiple myeloma and the increasing adoption of Carfilzomib as an effective treatment for this condition. Carfilzomib is a proteasome inhibitor, approved by health authorities for treating patients with multiple myeloma, a cancer of plasma cells. Its potent ability to target and inhibit the proteasome in cancer cells has made it a cornerstone in modern oncology treatment regimens.